deltatrials
Unknown PHASE3 NCT02770274

Cilostazol Following Peripheral Endovascular Procedures

Multi-center, Randomized Trial Comparing Dual Antiplatelet Therapy With CILOstazol Plus Aspirin Versus Aspirin Alone Following PERipheral Endovascular Procedures

Sponsor: Attikon Hospital

Conditions Peripheral Arterial Disease
Interventions Aspirin Cilostazol
Updated 10 times since 2017 Last updated: Jan 11, 2021 Started: Dec 31, 2016 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

Listed as NCT02770274, this PHASE3 trial focuses on Peripheral Arterial Disease and remains ongoing. Sponsored by Attikon Hospital, it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE3

    Status: Unknown Status → Unknown

  4. Feb 2023 — Jul 2024 [monthly]

    Unknown Status PHASE3

    Status: Recruiting → Unknown Status

  5. Feb 2021 — Feb 2023 [monthly]

    Recruiting PHASE3

▶ Show 5 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  2. Aug 2019 — Jan 2021 [monthly]

    Recruiting PHASE3

  3. Jul 2018 — Aug 2019 [monthly]

    Recruiting PHASE3

  4. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Attikon Hospital
  • University Hospital of Patras
Data source: Attikon Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Athens, Greece
  • • Pátrai, Greece